Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Advanced Quantitative Ultrasonography Methods to Evaluate Vision Degrading Myodesopsia
Author Affiliations & Notes
  • Jeffrey A Ketterling
    Weill Cornell Medicine, New York, New York, United States
  • Cameron Hoerig
    Weill Cornell Medicine, New York, New York, United States
  • Justin H. Nguyen
    VMR Consulting, Inc, California, United States
  • Jonathan Mamou
    Weill Cornell Medicine, New York, New York, United States
  • Cedric Venuat
    Quante Medical, France
  • J. Sebag
    VMR Consulting, Inc, California, United States
    Doheny Eye Institute ,Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Jeffrey Ketterling #9,295,448 , Code P (Patent); Cameron Hoerig None; Justin Nguyen None; Jonathan Mamou #9,295,448 , Code P (Patent); Cedric Venuat Quantel Medical, Code E (Employment); J. Sebag #9,295,448 , Code P (Patent)
  • Footnotes
    Support  NEI Grant EB032082
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 5561. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jeffrey A Ketterling, Cameron Hoerig, Justin H. Nguyen, Jonathan Mamou, Cedric Venuat, J. Sebag; Advanced Quantitative Ultrasonography Methods to Evaluate Vision Degrading Myodesopsia. Invest. Ophthalmol. Vis. Sci. 2024;65(7):5561.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Vision degrading myodesopsia (VDM) occurs when vitreous opacities cause clinically significant degradation in contrast sensitivity (CS) and visual quality-of-life (VQOL). Past studies demonstrated efficacy of quantitative ultrasound (QUS) in quantifying vitreous echodensities that correlated with CS and VQOL. However, prior QUS VDM studies utilized log-compressed envelope data which had two major drawbacks: 1) a limited ability to quantify the fundamental ultrasound (US) scattering properties of opacities that most affect CS and VQOL and 2) an inability to develop an absolute machine-independent QUS index. Advances in US scanner technology now permit access to raw radiofrequency (RF) data which we employed to compute system-independent QUS parameters that characterize the scattering properties of vitreous opacities.

Methods : 31 eyes from 18 patients (age ± years, 12 males) experiencing VDM had CS measured using Freiburg Acuity Contrast Testing. Vitreous was scanned with a 20-MHz annular array probe (B20, ABSolu, Quantel Medical, France). RF data were exported and data were processed to obtain backscatter coefficient (BSC) values and envelope statistic parameters. A total of 9 QUS parameters were generated that quantified scatterer size, concentration, and organization (Table 1). Linear and multi-linear regression were used to identify correlations between QUS parameters and CS.

Results : Six QUS parameters relating to scatterer size and concentration correlated with CS (p ≦ 0.02 for each). Multi-linear regression analysis revealed significant correlations between the set of QUS parameters and CS (R = 0.66, p < 0.001 ). The parameters with the strongest correlation to CS were spectral slope (R = -0.46, p < 0.003), which relates to scatterer size, and effective acoustic concentration (R = 0.47, p = 0.007), which relates to scatterer number density and relative acoustic impedance.

Conclusions : QUS parameters computed from RF data effectively quantified vitreous echodensities that correlate with CS. Unlike past QUS approaches to evaluate VDM, our method is based on the backscatter coefficient and envelope statistics which provides more accurate and robust measurements of acoustic scattering properties. Such system-independent QUS methods can provide information about the characteristics of vitreous opacities that most affect CS and VQOL, enabling new diagnostic approaches and evaluation of therapies.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×